The estimated Net Worth of Louis C Bock is at least $1.05 Million dollars as of 12 March 2018. Mr. Bock owns over 24,716 units of Zogenix Inc stock worth over $659,423 and over the last 21 years he sold ZGNX stock worth over $0. In addition, he makes $386,018 as Independent Director at Zogenix Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Bock ZGNX stock SEC Form 4 insiders trading
Louis has made over 4 trades of the Zogenix Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 24,716 units of ZGNX stock worth $389,277 on 12 March 2018.
The largest trade he's ever made was buying 1,839,645 units of Zogenix Inc stock on 29 November 2010 worth over $7,358,580. On average, Louis trades about 142,929 units every 111 days since 2004. As of 12 March 2018 he still owns at least 24,716 units of Zogenix Inc stock.
You can see the complete history of Mr. Bock stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Louis Bock biography
Louis C. Bock serves as Independent Director of the Company. Mr. Bock has served as a member of our board of directors since August 2006. Since August 2014, Mr. Bock has served as a Venture Partner at Santé Ventures, a venture capital firm. From September 1997 to July 2014, he was Managing Director of Scale Venture Partners, a venture capital firm. Previously, Mr. Bock held various positions in research, project management, business development and sales at Gilead Sciences, Inc., from September 1989 to September 1997. Prior to Gilead, he was a research associate at Genentech, Inc. from November 1987 to September 1989. From May 2005 to July 2018, Mr. Bock served as a director of Orexigen Therapeutics, Inc., and from September 2013 to April 2016, he served as a director of Heat Biologics, Inc., both biotechnology companies. In addition, Mr. Bock is responsible for Scale Venture Partners’ prior investments in Seattle Genetics, Prestwick Pharmaceuticals, Inc. and Somaxon Pharmaceuticals, Inc. Mr. Bock received his B.S. in Biology from California State University, Chico and his M.B.A. from California State University, San Francisco.
What is the salary of Louis Bock?
As the Independent Director of Zogenix Inc, the total compensation of Louis Bock at Zogenix Inc is $386,018. There are 13 executives at Zogenix Inc getting paid more, with Stephen Farr having the highest compensation of $10,346,800.
How old is Louis Bock?
Louis Bock is 55, he's been the Independent Director of Zogenix Inc since 2017. There are 13 older and 9 younger executives at Zogenix Inc. The oldest executive at Zogenix Inc is Cam Garner, 71, who is the Independent Chairman of the Board.
What's Louis Bock's mailing address?
Louis's mailing address filed with the SEC is C/O ZOGENIX, INC., 5959 HORTON STREET, SUITE 500, EMERYVILLE, CA, 94608.
Insiders trading at Zogenix Inc
Over the last 14 years, insiders at Zogenix Inc have traded over $5,100,850 worth of Zogenix Inc stock and bought 57,764,538 units worth $193,451,745 . The most active insiders traders include Advisors Llcperceptive Life..., Nicole Vitullo, and Jesse I Treu. On average, Zogenix Inc executives and independent directors trade stock every 34 days with the average trade being worth of $13,059,406. The most recent stock trade was executed by Erle T Mast on 1 February 2022, trading 1,250 units of ZGNX stock currently worth $15,000.
What does Zogenix Inc do?
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
What does Zogenix Inc's logo look like?
Complete history of Mr. Bock stock trades at Dynavax Technologies, Heat Biologics Inc, Horizon Therapeutics Plc, and Zogenix Inc
Zogenix Inc executives and stock owners
Zogenix Inc executives and other stock owners filed with the SEC include:
-
Stephen Farr,
President, Chief Executive Officer, Director -
Bradley Galer,
Executive Vice President, Chief Medical Officer -
Michael Smith,
Chief Financial Officer, Executive Vice President, Treasurer -
Gail Farfel,
Executive Vice President, Chief Development Officer -
Ashish Sagrolikar,
Executive Vice President, Chief Commercial Officer -
Dr. Stephen J. Farr,
Co-Founder, CEO, Pres & Director -
Shawnte M. Mitchell,
Exec. VP, Gen. Counsel & Sec. -
Dr. Bradley S. Galer,
Exec. VP & Chief Medical Officer -
Dr. Gail M. Farfel,
Exec. VP & Chief Devel. Officer -
Michael P. Smith,
Exec. VP, CFO & Treasurer -
Ashish M. Sagrolikar,
Exec. VP & COO -
Cam Garner,
Independent Chairman of the Board -
Erle Mast,
Independent Director -
Louis Bock,
Independent Director -
Mark Wiggins,
Independent Director -
James Breitmeyer,
Independent Director -
Renee Tannenbaum,
Independent Director -
Denelle Waynick,
Independent Director -
Mary Stutts,
Independent Director -
Caroline Loewy,
Independent Director -
Shawnte Mitchell,
Executive Vice President, General Counsel, Secretary -
Stephen H. Jenner,
VP of Marketing -
Bret E. Megargel,
VP of Corp. Devel. -
Melinda Baker,
Sr. Director of Corp. Communications -
Jeff D. Durflinger,
VP of Technical Operations & Product Supply -
Ann D Rhoads,
EVP, CFO, Treasurer & Sec. -
Thierry J.P. Darcis,
EVP / General Manager, Europe -
Venture Partners Ii, Lp Sca...,
-
Growth Partners Ii L P Chic...,
-
Advisors Llcperceptive Life...,
-
Roger Hawley,
Chief Executive Officer -
James C Blair,
Director -
Richard Scott Shively,
Chief Commercial Officer -
Nicole Vitullo,
10% owner -
Ken Haas,
Director -
Cynthia Y Robinson,
Chief Development Officer -
Brian K Halak,
10% owner -
Arda Phd Minocherhomjee,
Director -
Kurt Wheeler,
Director -
Kathleen K Schoemaker,
10% owner -
Lifesciences I, L.P.Clarus ...,
-
Parters Vii L P Domain,
10% owner -
Vi Associates, L.P. Dp,
10% owner -
Venture Partners Ii, Lp Sca...,
-
Brian H Dovey,
10% owner -
Partners Vi, L.P. Domain,
10% owner -
Jesse I Treu,
10% owner -
Mcnerney & Partners Lp Thom...,
-
Vii Associates Lp Dp,
10% owner -
Lifesciences I, L.P.Clarus ...,